Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

Kanji Takahashi,1 Masahito Ohji,2 Hiroko Terasaki,3 Shigeru Honda,4 Philippe Margaron,5 Tadhg Guerin,6 Mitsuko Yuzawa,7 On behalf of the EVEREST II Japanese investigators 1Department of Ophthalmology, Kansai Medical University, Osaka, Japan; 2Department of Ophthalmology, Shiga University...

Full description

Bibliographic Details
Main Authors: Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:Clinical Ophthalmology
Subjects:
Japanese
polypoidal choroidal vasculopathy
ranibizumab
neovascular age-related macular degeneration
verteporfin photodynamic therapy
Online Access:https://www.dovepress.com/efficacy-and-safety-of-ranibizumab-monotherapy-versus-ranibizumab-in-c-peer-reviewed-article-OPTH

Internet

https://www.dovepress.com/efficacy-and-safety-of-ranibizumab-monotherapy-versus-ranibizumab-in-c-peer-reviewed-article-OPTH

Similar Items